Darryl Jones

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

F. Lombardo, D. Fabbro, W. Jahnke, 2018, Journal of medicinal chemistry.

A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.

B. Cuenoud, R. Taylor, S. Charlton, 2010, Bioorganic & medicinal chemistry letters.

Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.

M. P. Dillon, R. Grotzfeld, Edward G. Lorenzana, 2019, ACS medicinal chemistry letters.

Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood.

M. Streiff, G. Thoma, J. Kovarik, 2011, Bioorganic & medicinal chemistry letters.

Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates

Daniel S. Palacios, M. P. Dillon, T. Abrams, 2018, ACS medicinal chemistry letters.

Potent and selective xanthine-based inhibitors of phosphodiesterase 5.

M. Zurini, R. Naef, S. Watson, 2007, Bioorganic & medicinal chemistry letters.

The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.

J. Fozard, S. Charlton, M. Gosling, 2014, Bioorganic & medicinal chemistry letters.